PPBT supply chain intelligence for Purple Biotech Ltd: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Purple Biotech Ltd (PPBT) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BMY | Bristol-Myers Squibb Company | 92% | We entered into a clinical collaboration and supply agreement with Bristol Myers Squibb Company (NYSE:BMY) for the phase 1/2 study of CM24 in combination with a programmed cell death protein 1 (PD-1)… |
| BMY | Bristol-Myers Squibb Company | 92% | Reciprocal relationship from BMY graph: Reciprocal relationship from PPBT graph: Reciprocal relationship from BMY graph: Reciprocal relationship from PPBT graph: We entered into a clinical collaborat… |
| BTTC | Black Titan Corporation | 72% | Reciprocal relationship from BTTC graph: ring from the University of West Ontario in 2006. We believe Mr. Lin’s extensive experience in investment and management qualifies him to serve on our board o… |
| CELG-RI | CELG-RI | 72% | letion of these trials and adversely affect our ability to advance the development of our therapeutic candidates. Even if we can enroll a sufficient number of patients in our clinical trials, delays … |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PPBT graph: letion of these trials and adversely affect our ability to advance the development of our therapeutic candidates. … |
| KMDA | Kamada Ltd. | 72% | Reciprocal relationship from KMDA graph: Reciprocal relationship from PPBT graph: Reciprocal relationship from KMDA graph: they will be utilized. Deductible carryforward losses and temporary differen… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CELG-RI | CELG-RI | 72% | letion of these trials and adversely affect our ability to advance the development of our therapeutic candidates. Even if we can enroll a sufficient number of patients in our clinical trials, delays … |
| CELG-RI | CELG-RI | 72% | Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PPBT graph: Reciprocal relationship from CELG-RI graph: Reciprocal relationship from PPBT graph: letion of these trials and ad… |
| AMORTIZATION-THE-GROUP | AMORTIZATION-THE-GROUP | 62% | re recognized initially at fair value less any directly attributable transaction costs. Subsequent measurement of financial liabilities Subsequent to initial recognition these financial liabilities a… |
| BRISTOL-MYERS-SQUIBB-COMPANY | BRISTOL-MYERS-SQUIBB-COMPANY | 62% | ion of these trials and adversely affect our ability to advance the development of our therapeutic candidates. 15 Even if we can enroll a sufficient number of patients in our clinical trials, delays … |
| FAHN-KANNE-CONTROL-MANAGEMENT-LTD | FAHN-KANNE-CONTROL-MANAGEMENT-LTD | 62% | ached as Exhibit 4.9 to this Annual Report on Form 20-F. Nominations Committee In September 2020, our Board established a nominations committee, whose role is (among other things) to identify, review… |
| FAMEWAVE-LTD | FAMEWAVE-LTD | 62% | lower than its carrying amount. Accordingly, the Company recognized a full impairment loss of USD 6,172 thousand. B. Acquisition of Famewave On January 7, 2020 the Company completed the purchase of 1… |
| KITOV-PHARMACEUTICALS-HOLDINGS-LTD | KITOV-PHARMACEUTICALS-HOLDINGS-LTD | 62% | U.S. broker-dealer selling penny stock to anyone other than an established customer or “accredited investor” (generally, an individual with net worth in excess of $1,000,000 or an annual income excee… |
| KITOV-PHARMA-LTD | KITOV-PHARMA-LTD | 62% | U.S. broker-dealer selling penny stock to anyone other than an established customer or “accredited investor” (generally, an individual with net worth in excess of $1,000,000 or an annual income excee… |
| MAINROM-LINE-LOGISTICS-LTD | MAINROM-LINE-LOGISTICS-LTD | 62% | U.S. broker-dealer selling penny stock to anyone other than an established customer or “accredited investor” (generally, an individual with net worth in excess of $1,000,000 or an annual income excee… |
| PASSIVE-FOREIGN-INVESTMENT-COMPANY | PASSIVE-FOREIGN-INVESTMENT-COMPANY | 62% | U.S. broker-dealer selling penny stock to anyone other than an established customer or “accredited investor” (generally, an individual with net worth in excess of $1,000,000 or an annual income excee… |
| PURPLE-GMBH | PURPLE-GMBH | 62% | lower than its carrying amount. Accordingly, the Company recognized a full impairment loss of USD 6,172 thousand. B. Acquisition of Famewave On January 7, 2020 the Company completed the purchase of 1… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| PPBT-DEBT | Debt stack $184,000 | 90% | Market cache reports total debt of $184,000. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| PPBT-OWNER-MORGAN-STANLEY | MORGAN STANLEY | 90% | 13F overlay lists MORGAN STANLEY as top holder; 2 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| FISI | Financial Institutions, Inc. | 100.00 | 2 | |
| MMTX | Miluna Acquisition Corp | 100.00 | 2 | |
| KMDA | Kamada Ltd. | 100.00 | 1 | ['supplier'] |
| BMY | Bristol-Myers Squibb Company | 100.00 | 1 | ['supplier'] |
| ONMD | OneMedNet Corporation | 100.00 | 2 | |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 100.00 | 1 | ['customer', 'supplier'] |
| BEAM | Beam Therapeutics Inc. | 50.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 50.00 | 2 | |
| CHKP | Check Point Software Technologies Ltd. | 50.00 | 2 | |
| CHRS | Coherus Oncology, Inc. | 50.00 | 2 | |
| DYN | Dyne Therapeutics, Inc. | 50.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 50.00 | 2 | |
| FULC | Fulcrum Therapeutics, Inc. | 50.00 | 2 | |
| CUE | Cue Biopharma, Inc. | 50.00 | 2 | |
| ALLR | Allarity Therapeutics, Inc. | 50.00 | 2 | |
| BAX | Baxter International Inc. | 50.00 | 2 | |
| SDGR | Schrödinger, Inc. | 50.00 | 2 | |
| GILT | Gilat Satellite Networks Ltd. | 50.00 | 2 | |
| AZN | AstraZeneca PLC | 50.00 | 2 | |
| FATE | Fate Therapeutics, Inc. | 50.00 | 2 |